You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH):HB0056注射液獲得藥物臨牀試驗許可
格隆匯 02-21 17:27

格隆匯2月21日丨華海藥業(600521.SH)公佈,下屬子公司上海華奧泰生物藥業股份有限公司和華博生物醫藥技術(上海)有限公司(華奧泰下屬全資子公司,簡稱“華博生物”)收到國家藥品監督管理局覈準簽發的HB0056注射液的《藥物臨牀試驗批準通知書》。HB0056是以抗TSLP(胸腺基質淋巴細胞生成素)人源化單克隆抗體爲親本抗體,在N端連接抗IL-11(白細胞介素-11)單鏈納米抗體的雙特異性抗體,能高特異性地靶向TSLP和IL-11這兩個靶點。研究表明,TSLP在多種炎症性皮膚病及呼吸系統疾病的發病中發揮重要作用。IL-11是一種具有多效性的細胞因子,參與多種自免疾病及腫瘤的發生和發展。TSLP和IL-11均以不同的機制參與誘導Th2(輔助型T細胞2)反應、氣道炎症和哮喘的發病機制,兩者可以互補作用來影響該疾病。同時阻斷TSLP和IL-11通路可以爲哮喘患者提供更好的療效,特別是對於那些在不受控制的炎症後發生氣道重塑和纖維化的患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account